Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service vitreoretinal surgery cases in North Dakota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 137 | 20% |
| 2020 | 3 | 165 | 22% |
| 2021 | 4 | 178 | 25% |
Pars plana vitrectomy and retinal detachment repair. Professional codes (what the surgeon bills): CPT 67036, 67040, 67041, 67042, 67108, 67113.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in North Dakota; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Cataract & MIGS | 23 | 8,264+1.9%/yr | +1.9%/yr | 82.01.2× | 78% | 9,110 in 2030+1.6%/yr |
Vitreoretinal surgery in every state, and its device makers · Every procedure market in North Dakota · Every state · Compare with Ohio
| ≈ 120 |
| – |
| 2026 est. | ≈ 120 | – |
| 2022 | 4 | 260 | 29% |
| 2023 | 2 | 159 | 34% |
| 2024 | 2 | 184 | 37% |
| 2025 from claims | – | 121 98–142 | 39% |
| 2026 forecast | – | 124 97–156 | 38% |
| 2027 forecast | – | 125 93–165 | 39% |
| 2028 forecast | – | 126 89–174 | 40% |
| 2029 forecast | – | 127 86–182 | 41% |
| 2030 forecast | – | 127 83–189 | 41% |
In 2025, 27% hospital outpatient, 73% surgery center. The share outside the hospital has moved −27 pts since 2022.
| −5.7%/yr |
| 2.0 |
| 42% |
| 2,740 in 20300%/yr |
| Missouri | 35 | 1,908−0.3%/yr | −0.3%/yr | 3.1 | 51% | 1,740 in 2030−1.5%/yr |
| Michigan | 23 | 1,526−8.8%/yr | −8.8%/yr | 1.8 | 29% | 1,320 in 2030−2.3%/yr |
| Indiana | 24 | 1,476−4.2%/yr | −4.2%/yr | 2.1 | 74% | 1,530 in 2030+0.6%/yr |
| Wisconsin | 18 | 1,472−1%/yr | −1%/yr | 2.6 | 29% | 1,730 in 2030+2.7%/yr |
| Minnesota | 21 | 1,192−4.8%/yr | −4.8%/yr | 2.7 | 73% | 1,540 in 2030+4.3%/yr |
| Kansas | 18 | 1,141−5.2%/yr | −5.2%/yr | 2.8 | 60% | 1,150 in 2030+0.2%/yr |
| Iowa | 14 | 772+0.4%/yr | +0.4%/yr | 1.8 | 67% | 880 in 2030+2.2%/yr |
| Nebraska | 9 | 735−1.3%/yr | −1.3%/yr | 2.8 | 72% | 740 in 20300%/yr |
| South Dakota | 7 | 578+4.1%/yr | +4.1%/yr | 4.5 | 100% | 1,010 in 2030+9.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Bausch & Lomb leads with 30% of company spending on these surgeons in 2025, −20 pts on 2024.
In 2025, 9 companies reported engagement with North Dakota’s surgeons worth $44K in consulting, speaking, meals and travel tied to these products, about $22K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 0 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.